Madison Avenue Partners, LP Sage Therapeutics, Inc. Transaction History
Madison Avenue Partners, LP
- $934 Million
- Q2 2025
A detailed history of Madison Avenue Partners, LP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Madison Avenue Partners, LP holds 6,077,065 shares of SAGE stock, worth $52.7 Million. This represents 5.93% of its overall portfolio holdings.
Number of Shares
6,077,065
Previous 4,477,798
35.72%
Holding current value
$52.7 Million
Previous $35.6 Million
55.69%
% of portfolio
5.93%
Previous 4.6%
Shares
2 transactions
Others Institutions Holding SAGE
# of Institutions
222Shares Held
51.1MCall Options Held
759KPut Options Held
440K-
Black Rock Inc. New York, NY5.22MShares$45.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$28.3 Million0.0% of portfolio
-
Hudson Bay Capital Management LP Greenwich, CT1.95MShares$16.9 Million0.07% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.92MShares$16.6 Million0.01% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.52MShares$13.2 Million0.02% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $516M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...